Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInventory AverageInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Unicycive Therapeutics (UNCY) Return on Capital Employed (2021 - 2026)

Unicycive Therapeutics filings provide 3 years of Return on Capital Employed readings, the most recent being 291.95% for Q4 2024.

  • On a quarterly basis, Return on Capital Employed fell 318742.0% to 291.95% in Q4 2024 year-over-year; TTM through Dec 2024 was 291.95%, a 318742.0% decrease, with the full-year FY2024 number at 2697.77%, up 246771.0% from a year prior.
  • Return on Capital Employed hit 291.95% in Q4 2024 for Unicycive Therapeutics, down from 93.55% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 2895.47% in Q4 2023 to a low of 857.52% in Q1 2024.
  • Median Return on Capital Employed over the past 3 years was 201.62% (2023), compared with a mean of 267.85%.
  • Biggest five-year swings in Return on Capital Employed: surged 345723bps in 2023 and later crashed -318742bps in 2024.
  • Unicycive Therapeutics' Return on Capital Employed stood at 561.76% in 2022, then skyrocketed by 615bps to 2895.47% in 2023, then plummeted by -110bps to 291.95% in 2024.
  • The last three reported values for Return on Capital Employed were 291.95% (Q4 2024), 93.55% (Q3 2024), and 81.38% (Q2 2024) per Business Quant data.